ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)'s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.79 and traded as high as $3.69. ProQR Therapeutics shares last traded at $3.67, with a volume of 234,296 shares traded.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on PRQR. Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. HC Wainwright lifted their target price on ProQR Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $7.13.
Check Out Our Latest Report on PRQR
ProQR Therapeutics Stock Up 1.9 %
The stock has a 50 day moving average price of $2.79 and a 200-day moving average price of $2.20.
Hedge Funds Weigh In On ProQR Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. EP Wealth Advisors LLC bought a new stake in ProQR Therapeutics during the first quarter valued at about $26,000. Acadian Asset Management LLC purchased a new stake in shares of ProQR Therapeutics in the first quarter worth about $56,000. BNP Paribas Financial Markets lifted its position in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 19,100 shares in the last quarter. OneDigital Investment Advisors LLC lifted its position in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after buying an additional 15,550 shares in the last quarter. Finally, Ikarian Capital LLC lifted its position in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company's stock worth $1,098,000 after buying an additional 10,958 shares in the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.
ProQR Therapeutics Company Profile
(
Get Free Report)
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Further Reading
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
